Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings, Inc. (BPTH) generates frequent news as a clinical-stage biotechnology company developing RNAi nanoparticle drugs using its proprietary DNAbilize® liposomal antisense platform. Company announcements focus on progress across its oncology and obesity programs, including clinical trial updates, preclinical data, intellectual property developments, and corporate actions.
News coverage commonly highlights the Phase 2 trial of prexigebersen (BP1001) in acute myeloid leukemia and other blood cancers, where Bio-Path has reported extended treatment durability and complete remissions in elderly AML patients treated with combinations that include prexigebersen. Regular updates also cover the Phase 1/1b trial of BP1001-A in advanced solid tumors, including reports of tumor reduction and stable disease in heavily pretreated gynecologic cancer patients.
Another recurring theme in BPTH news is the exploration of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Press releases describe preclinical studies in muscle and liver cell models showing improved insulin sensitivity and restored insulin signaling, along with milestones in the path toward an Investigational New Drug (IND) application.
Investors following BPTH news will also see updates on BP1002 for relapsed or refractory AML, including venetoclax-resistant patients, and BP1003 targeting STAT3, as well as reports on patent issuances that expand the company’s DNAbilize® intellectual property portfolio. In addition, SEC filings and corporate press releases provide information on financing efforts, operational pauses, leadership changes, and the company’s transition from Nasdaq listing to trading on over-the-counter markets. This news page aggregates these developments so readers can track Bio-Path’s clinical, scientific, and corporate trajectory over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.